BioCryst Pharmaceuticals Inc (BCRX) stock
BCRXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$7.50+0.05 (+0.67%)
Close on Nov 17, 2026Market cap $1.92BP/E –Yield –
BioCryst Pharmaceuticals operating cash flow
Operating cash flow is the cash the business generates from its day-to-day operations.
BioCryst Pharmaceuticals's operating cash flow for the twelve months ending Jun 30, 2026 was $376.14M, up 2136.6% year over year. For fiscal 2025 it was $347.37M. The highest annual figure on record is $347.37M in fiscal 2025.
Annual operating cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $347.37M | – |
| FY2024 | Dec 31, 2024 | -$52.02M | – |
| FY2023 | Dec 31, 2023 | -$95.14M | – |
| FY2022 | Dec 31, 2022 | -$161.85M | – |
| FY2021 | Dec 31, 2021 | -$142.16M | – |
| FY2020 | Dec 31, 2020 | -$135.11M | – |
| FY2019 | Dec 31, 2019 | -$89.58M | – |
| FY2018 | Dec 31, 2018 | -$92.57M | – |
| FY2017 | Dec 31, 2017 | -$41.14M | – |
| FY2016 | Dec 31, 2016 | -$53.44M | – |
| FY2015 | Dec 31, 2015 | -$13.12M | – |
| FY2014 | Dec 31, 2014 | -$38.55M | – |
| FY2013 | Dec 31, 2013 | -$26.53M | – |
| FY2012 | Dec 31, 2012 | -$37.40M | – |
| FY2011 | Dec 31, 2011 | -$32.25M | – |
| FY2010 | Dec 31, 2010 | -$28.56M | – |
| FY2009 | Dec 31, 2009 | -$16.22M | – |
Quarterly operating cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $104.34M | +152.6% |
| Q1 FY2026 | Mar 31, 2026 | -$61.79M | – |
| Q4 FY2025 | Dec 31, 2025 | $291.96M | – |
| Q3 FY2025 | Sep 30, 2025 | $41.62M | +404.8% |
| Q2 FY2025 | Jun 30, 2025 | $41.30M | – |
| Q1 FY2025 | Mar 31, 2025 | -$27.52M | – |
| Q4 FY2024 | Dec 31, 2024 | -$5.21M | – |
| Q3 FY2024 | Sep 30, 2024 | $8.25M | – |
| Q2 FY2024 | Jun 30, 2024 | -$1.37M | – |
| Q1 FY2024 | Mar 31, 2024 | -$53.68M | – |
| Q4 FY2023 | Dec 31, 2023 | -$8.92M | – |
| Q3 FY2023 | Sep 30, 2023 | -$19.90M | – |
| Q2 FY2023 | Jun 30, 2023 | -$18.81M | – |
| Q1 FY2023 | Mar 31, 2023 | -$47.51M | – |
| Q4 FY2022 | Dec 31, 2022 | -$23.85M | – |
| Q3 FY2022 | Sep 30, 2022 | -$32.44M | – |
| Q2 FY2022 | Jun 30, 2022 | -$27.76M | – |
| Q1 FY2022 | Mar 31, 2022 | -$77.80M | – |
| Q4 FY2021 | Dec 31, 2021 | -$32.46M | – |
| Q3 FY2021 | Sep 30, 2021 | -$23.28M | – |
| Q2 FY2021 | Jun 30, 2021 | -$25.41M | – |
| Q1 FY2021 | Mar 31, 2021 | -$61.01M | – |
| Q4 FY2020 | Dec 31, 2020 | -$42.53M | – |
| Q3 FY2020 | Sep 30, 2020 | -$38.26M | – |
| Q2 FY2020 | Jun 30, 2020 | -$31.04M | – |
| Q1 FY2020 | Mar 31, 2020 | -$23.28M | – |
| Q4 FY2019 | Dec 31, 2019 | -$10.45M | – |
| Q3 FY2019 | Sep 30, 2019 | -$27.64M | – |
| Q2 FY2019 | Jun 30, 2019 | -$24.50M | – |
| Q1 FY2019 | Mar 31, 2019 | -$27.00M | – |
| Q4 FY2018 | Dec 31, 2018 | -$23.99M | – |
| Q3 FY2018 | Sep 30, 2018 | -$35.03M | – |
| Q2 FY2018 | Jun 30, 2018 | -$13.90M | – |
| Q1 FY2018 | Mar 31, 2018 | -$19.65M | – |
| Q4 FY2017 | Dec 31, 2017 | -$10.52M | – |
| Q3 FY2017 | Sep 30, 2017 | -$12.43M | – |
| Q2 FY2017 | Jun 30, 2017 | -$9.67M | – |
| Q1 FY2017 | Mar 31, 2017 | -$8.53M | – |
| Q4 FY2016 | Dec 31, 2016 | -$5.85M | – |
| Q3 FY2016 | Sep 30, 2016 | -$17.56M | – |
See a number that looks wrong?